The Pharma Patent Cliff: $300B in Drug Sales Goes Off Patent by 2030

The pharma patent cliff is the steepest the industry has faced. Between 2025 and 2030, more than $300 billion in annual prescription-drug revenue loses market exclusivity, according to Evaluate Pharma — roughly one-sixth of the industry’s sales and about three times the scale of the first great cliff in 2012. Some 190 drugs go off patent by 2030, 69 of them blockbusters, and the names at risk are the ones that built the last decade of pharma earnings. For anyone who files, values or defends life-science IP, the cliff is not a distant macro story; it is a redrawing of who owns what, and for how long.

What the Pharma Patent Cliff Means in 2026

A patent cliff is what happens when a drug’s core exclusivity ends and lower-priced competition arrives. For a small molecule that means generics; for a biologic it means biosimilars. Either way, the originator’s sales for that product can fall by the majority within a year, and when several blockbusters expire in the same window the effect compounds across a whole portfolio.

The pharma patent cliff now underway is unusually concentrated. Evaluate Pharma puts the revenue losing exclusivity between 2025 and 2030 at over $300 billion; industry reporting counts roughly 190 products going off patent by 2030, 69 of them blockbusters selling more than $1 billion a year. The 2012 cliff, which erased around $100 billion as Lipitor, Plavix and others fell, was severe at the time. This one is about three times larger, and it lands on a portfolio that has shifted heavily toward biologics, where the follow-on economics work differently.

The distinction between small-molecule generics and biosimilars matters because the erosion curves differ. A generic can capture most of a market in months; a biosimilar, harder to make and to switch patients onto, erodes the originator more slowly but just as surely. Reading which of your assets faces which kind of competition, and when, is the first output of any credible cliff analysis.

The Blockbusters Going Over the Edge

The cliff is defined by a handful of very large products. The single biggest exposure is Merck’s Keytruda (pembrolizumab), the world’s top-selling drug at $29.5 billion in 2024 sales, up 18% year on year. Its key US patents on the intravenous formulation expire in 2028, and Merck is racing a subcutaneous version and new combinations to soften the drop.

Others are already falling. Johnson & Johnson’s Stelara (ustekinumab), which generated about $10.4 billion in 2024 — $6.72 billion of it in the US — met its first US biosimilars in January 2025, with several competitors launching through the year. The anticoagulants Eliquis (Bristol Myers Squibb / Pfizer) and Xarelto (J&J / Bayer) and the oncology mainstay Opdivo (Bristol Myers Squibb) all sit in the 2025–2028 loss-of-exclusivity window, and the FDA cleared a first generic of Xarelto in 2025.

• Keytruda (Merck) — $29.5B in 2024; key US patents expire 2028.
• Stelara (J&J) — ~$10.4B in 2024; US biosimilars began launching January 2025.
• Eliquis (BMS/Pfizer) — generic entry enabled in the mid-to-late-2020s under settlement.
• Opdivo (BMS) — US biologic exclusivity easing toward 2028.
• Xarelto (J&J/Bayer) — first US generic approved in 2025.

One giant is often misfiled into this cliff: Novo Nordisk’s semaglutide (Ozempic, Wegovy, Rybelsus). Its core US patent runs to December 5, 2031, with method-of-use patents reaching further, so the GLP-1 cliff is the next one, in the early 2030s — a reminder that patent-cliff planning is a rolling exercise, not a single event.

How Biosimilars and Generics Erode Revenue

The reason a cliff hurts is the speed of price and share erosion once competition arrives. IQVIA’s analysis of the US biosimilar market found biosimilars typically launch at 65–80% of the reference product’s price, and that net prices after rebates can fall 50–70%, with average selling prices dropping about 45% by the third year in markets with post-2018 launches. On the branded side, market-share loss can exceed 80% within the first year of competition — the pattern that saw Lipitor’s sales fall 71% in the year after its 2011 expiry.

That erosion is a transfer, not just a loss. IQVIA credits biosimilars with $20.2 billion in US savings in 2024 alone and $56.2 billion cumulatively since 2015 — money that moves from originators to payers, patients and biosimilar makers. For the originator, the strategic question is not whether erosion happens but how much runway lifecycle management can buy before it does.

Sizing that transfer is a market-research exercise in its own right. The revenue at stake, the eligible patient population and the realistic biosimilar uptake curve are exactly the inputs behind a defensible market model — the kind we walk through in our biotech market sizing case study.

The Patent Strategies That Delay the Cliff

Originators do not accept the cliff passively. The dominant tactic is the patent thicket — layering secondary patents on formulation, dosing, manufacturing and devices around a drug so that biosimilar makers must clear dozens of claims before entering. The canonical example is AbbVie’s Humira (adalimumab): the advocacy group I-MAK documented 247 US patent applications filed on the drug, more than 130 granted, and 89% of those applications filed after the FDA approved Humira in 2002 — a strategy that stretched US exclusivity to 2023, years beyond the original compound patent.

The same playbook recurs across the cliff’s biggest names: subcutaneous reformulations, new indications, fixed-dose combinations and authorized generics all aim to move revenue onto fresh exclusivity before the old patent lapses. None of it is inherently improper — a genuine new formulation deserves protection — but the line between legitimate lifecycle management and evergreening is exactly where litigation and regulatory scrutiny now concentrate.

For a company on either side of that line, mapping the thicket is unavoidable. A biosimilar entrant needs a freedom-to-operate read on every live secondary patent; an originator needs to know which of its own claims will actually survive challenge. Both start from the same primary-source map of who holds what, which is the work of a biotech patent landscape.

Regulatory Pushback: The FTC and the Orange Book

The evergreening strategy has drawn a sustained regulatory response. Since late 2023 the US Federal Trade Commission has run a campaign against improper Orange Book patent listings — the listings that can trigger automatic 30-month stays on generic approval. In November 2023 it challenged more than 100 patents tied to inhalers and autoinjectors; in April 2024 it disputed over 300 listings across 20 products in diabetes, weight-loss and respiratory care; and in May 2025 it renewed the campaign against more than 200 listings across 17 products, naming companies including Novartis, Teva and Mylan Specialty.

The courts have backed the pressure. In December 2024 a federal appellate decision upheld an order requiring Teva to delist asthma-inhaler patents from the Orange Book, validating the FTC’s theory that device patents were being used to block competition. For IP strategists the message is clear: a listing strategy that once bought years of delay now carries real antitrust and delisting risk, and the cliff cannot be papered over as easily as it once was.

What the Pharma Patent Cliff Means for IP Strategy

The cliff turns patent intelligence into a board-level input. For originators, it drives lifecycle planning — which reformulations to file, which indications to pursue, and where a defensive publication beats a vulnerable secondary patent. For biosimilar and generic developers, it sets the entry calendar and the freedom-to-operate workload. For investors and acquirers, a target’s exposure to loss of exclusivity is a direct input to valuation and to M&A IP due diligence.

All of it rests on reading the primary record accurately: expiry dates and their secondary-patent extensions, the biosimilar pipeline against each target, and the market that opens as exclusivity ends. That is landscape and market-sizing work, and it is where a rigorous, source-cited analysis separates a defensible strategy from a hopeful one. The cliff rewards the teams that mapped it early.

How to Map Your Exposure to the Pharma Patent Cliff

Turning the cliff from a headline into a plan takes a disciplined, primary-source workflow. The same four steps apply whether you are an originator defending a franchise, a biosimilar developer timing an entry, or an investor pricing a portfolio — only the conclusion you draw from them changes.

1. Inventory every material patent and its true expiry. Separate the compound patent from the secondary layer — formulation, dosing, device and manufacturing claims — because the last of these, not the first, sets the real date competition can begin.
2. Check the Orange Book and Purple Book against each product. The FDA’s Purple Book lists licensed biologics and their biosimilars, and the Orange Book lists small-molecule patents and exclusivities; both are the public record a challenger will work from first.
3. Map the follow-on pipeline. Count the biosimilars or generics already filed or approved against each target, and model an uptake curve from comparable past launches rather than a straight line.
4. Size the revenue at risk and the market that opens. Convert exclusivity dates and uptake curves into a defensible TAM/SAM/SOM view, so the cliff becomes a number a board or an investment committee can act on.

Done well, the exercise is not a doomsday count but a strategy tool. It tells an originator where a genuine reformulation can extend a franchise and where a weak secondary patent invites a challenge; it tells a biosimilar maker which target clears fastest; and it tells an acquirer exactly how much of a target’s revenue is living on borrowed time. The pharma patent cliff is only a threat to the teams that let it arrive unmapped.

Why Loss of Exclusivity Rarely Matches the Patent Expiry Date

The most common modelling error in pharma patent cliff analysis is treating a composition-of-matter patent’s twenty-year term as the revenue event. It almost never is. The date that matters commercially is loss of exclusivity, and that date is set by a stack of overlapping rights that expire on different clocks — some granted by the patent office, some by the regulator.

On the patent side, Hatch-Waxman patent term extension under 35 U.S.C. 156 restores part of the term lost to FDA review. The restoration is capped at five years, and the extended term cannot run beyond fourteen years from the date of FDA approval. Only one patent per approved product may be extended, so the choice of which patent to put forward is itself a strategic decision made years before the cliff arrives.

Running alongside it is regulatory exclusivity, which the FDA grants independently of any patent. A new chemical entity carries five years, though a generic applicant may file an abbreviated application with a paragraph IV certification after four. Orphan drug designation carries seven years. Qualifying paediatric studies add a further six months under section 505A of the Federal Food, Drug, and Cosmetic Act, and that six months attaches to both the patents and the exclusivities, moving the whole stack.

Biologics run on a different clock again. Under the Biologics Price Competition and Innovation Act, a reference product receives twelve years of exclusivity from first licensure, and no biosimilar application may be submitted during the first four. This is a large part of why biologic cliffs arrive later, and then erode more slowly, than small-molecule cliffs.

Litigation timing layers on top. Where a paragraph IV certification is met with an infringement suit filed within forty-five days, approval of the generic application is stayed for up to thirty months. That single procedural step can move a revenue cliff by more than two years without any change to the underlying patent.

Outside the United States the mechanics differ but the principle holds. In Europe a supplementary protection certificate under Regulation (EC) No 469/2009 can add up to five years after the basic patent expires, with a further six-month paediatric extension available under Regulation (EC) No 1901/2006. The result is that a single product frequently goes off patent in different territories in different years.

The practical takeaway for anyone building an exposure model: work from the latest-expiring right in each market, not from the headline patent. A pharma patent cliff model built on patent expiry dates alone will misdate the revenue event by years, and it will do so in both directions.

How PerspireIP Can Help

At PerspireIP, our team helps innovators and businesses protect what they build. Whether you need a patent or trademark search, prior-art analysis, or an IP strategy tailored to your goals, we can help. Contact our team to discuss your next step.

Frequently Asked Questions